{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:27:19Z","timestamp":1791073639217,"version":"4.1.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,8,10]],"date-time":"2012-08-10T00:00:00Z","timestamp":1344556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s00223-012-9630-5","type":"journal-article","created":{"date-parts":[[2012,8,9]],"date-time":"2012-08-09T03:23:22Z","timestamp":1344482602000},"page":"225-243","source":"Crossref","is-referenced-by-count":80,"title":["Management of Glucocorticoid-Induced Osteoporosis"],"prefix":"10.1007","volume":"91","author":[{"given":"R.","family":"Rizzoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. D.","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Dere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Devogelaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Diez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Laslop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mitlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ralston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Werhya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,10]]},"reference":[{"issue":"10","key":"9630_CR1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18(10):1319\u20131328","journal-title":"Osteoporos Int"},{"issue":"10","key":"9630_CR2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","volume":"13","author":"TP Staa van","year":"2002","unstructured":"van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13(10):777\u2013787","journal-title":"Osteoporos Int"},{"issue":"1","key":"9630_CR3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11926-007-0026-x","volume":"9","author":"JE Compston","year":"2007","unstructured":"Compston JE (2007) Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 9(1):78\u201384","journal-title":"Curr Rheumatol Rep"},{"key":"9630_CR4","doi-asserted-by":"crossref","unstructured":"Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost\u2013utility analysis. Health Technol Assess 11(7):iii\u2013iv, ix\u2013xi, 1\u2013231","DOI":"10.3310\/hta11070"},{"issue":"7053","key":"9630_CR5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/bmj.313.7053.344","volume":"313","author":"LJ Walsh","year":"1996","unstructured":"Walsh LJ, Wong CA, Pringle M, Tattersfield AE (1996) Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313(7053):344\u2013346","journal-title":"BMJ"},{"issue":"2","key":"9630_CR6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/qjmed\/93.2.105","volume":"93","author":"TP Van Staa","year":"2000","unstructured":"Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C (2000) Use of oral corticosteroids in the United Kingdom. QJM 93(2):105\u2013111","journal-title":"QJM"},{"issue":"3","key":"9630_CR7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bone.2011.05.007","volume":"49","author":"A Diez-Perez","year":"2011","unstructured":"Diez-Perez A, Hooven FH, Adachi JD, Adami S, Anderson FA, Boonen S, Chapurlat R, Compston JE, Cooper C, Delmas P, Greenspan SL, Lacroix AZ, Lindsay R, Netelenbos JC, Pfeilschifter J, Roux C, Saag KG, Sambrook P, Silverman S, Siris ES, Watts NB, Nika G, Gehlbach SH (2011) Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 49(3):493\u2013498","journal-title":"Bone"},{"issue":"8","key":"9630_CR8","first-page":"1651","volume":"33","author":"KG Saag","year":"2006","unstructured":"Saag KG, Gehlbach SH, Curtis JR, Youket TE, Worley K, Lange JL (2006) Trends in prevention of glucocorticoid-induced osteoporosis. J Rheumatol 33(8):1651\u20131657","journal-title":"J Rheumatol"},{"issue":"1","key":"9630_CR9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.61.1.32","volume":"61","author":"B Gudbjornsson","year":"2002","unstructured":"Gudbjornsson B, Juliusson UI, Gudjonsson FV (2002) Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 61(1):32\u201336","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"9630_CR10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","volume":"39","author":"TP Van Staa","year":"2000","unstructured":"Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39(12):1383\u20131389","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"9630_CR11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-003-1548-3","volume":"15","author":"M Steinbuch","year":"2004","unstructured":"Steinbuch M, Youket TE, Cohen S (2004) Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 15(4):323\u2013328","journal-title":"Osteoporos Int"},{"issue":"6","key":"9630_CR12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"TP Staa Van","year":"2000","unstructured":"Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15(6):993\u20131000","journal-title":"J Bone Miner Res"},{"issue":"6","key":"9630_CR13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","volume":"19","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton IL, Tenenhouse A, Reeve J, Silman AJ, Pols HA, Eisman JA, McCloskey EV, Mellstrom D (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19(6):893\u2013899","journal-title":"J Bone Miner Res"},{"issue":"1","key":"9630_CR14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.53.1.18","volume":"53","author":"H Kroger","year":"1994","unstructured":"Kroger H, Honkanen R, Saarikoski S, Alhava E (1994) Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis\u2014a population based study. Ann Rheum Dis 53(1):18\u201323","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"9630_CR15","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.berh.2005.07.002","volume":"19","author":"JD Adachi","year":"2005","unstructured":"Adachi JD, Papaioannou A (2005) In whom and how to prevent glucocorticoid-induced osteoporosis. Best Pract Res Clin Rheumatol 19(6):1039\u20131064","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"9630_CR16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.2001.16.3.581","volume":"16","author":"TP Staa van","year":"2001","unstructured":"van Staa TP, Leufkens HG, Cooper C (2001) Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 16(3):581\u2013588","journal-title":"J Bone Miner Res"},{"issue":"3","key":"9630_CR17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jocd.2011.05.014","volume":"14","author":"ES Leib","year":"2011","unstructured":"Leib ES, Saag KG, Adachi JD, Geusens PP, Binkley N, McCloskey EV, Hans DB (2011) Official positions for FRAX clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX of the 10\u00a0year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX. J Clin Densitom 14(3):212\u2013219","journal-title":"J Clin Densitom"},{"issue":"5","key":"9630_CR18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00002018-200831050-00005","volume":"31","author":"M Etminan","year":"2008","unstructured":"Etminan M, Sadatsafavi M, Ganjizadeh Zavareh S, Takkouche B, FitzGerald JM (2008) Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis. Drug Saf 31(5):409\u2013414","journal-title":"Drug Saf"},{"issue":"1","key":"9630_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1081-1206(10)60400-0","volume":"100","author":"JH Wlodarczyk","year":"2008","unstructured":"Wlodarczyk JH, Gibson PG, Caeser M (2008) Impact of inhaled corticosteroids on cortisol suppression in adults with asthma: a quantitative review. Ann Allergy Asthma Immunol 100(1):23\u201330","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"9630_CR20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00198-004-1606-5","volume":"15","author":"TP Van Staa","year":"2004","unstructured":"Van Staa TP, Bishop N, Leufkens HG, Cooper C (2004) Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos Int 15(10):785\u2013791","journal-title":"Osteoporos Int"},{"issue":"3","key":"9630_CR21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/rheumatology\/27.3.215","volume":"27","author":"JW Bijlsma","year":"1988","unstructured":"Bijlsma JW, Duursma SA, Bosch R, Raymakers JA, Huber-Bruning O (1988) Acute changes in calcium and bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis. Br J Rheumatol 27(3):215\u2013219","journal-title":"Br J Rheumatol"},{"issue":"9","key":"9630_CR22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/ard.45.9.757","volume":"45","author":"JW Bijlsma","year":"1986","unstructured":"Bijlsma JW, Duursma SA, Huber-Bruning O (1986) Bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis. Ann Rheum Dis 45(9):757\u2013760","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"9630_CR23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/BF02207199","volume":"11","author":"MJ Van der Veen","year":"1992","unstructured":"Van der Veen MJ, Bijlsma JW (1992) Effects of different regimes of corticosteroid treatment on calcium and bone metabolism in rheumatoid arthritis. Clin Rheumatol 11(3):388\u2013392","journal-title":"Clin Rheumatol"},{"key":"9630_CR24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1042\/bj2370447","volume":"237","author":"R Rizzoli","year":"1986","unstructured":"Rizzoli R, von Tscharner V, Fleisch H (1986) Increase of adenylate cyclase catalytic-unit activity by dexamethasone in rat osteoblast-like cells. Biochem J 237:447\u2013454","journal-title":"Biochem J"},{"issue":"9","key":"9630_CR25","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1056\/NEJMoa040367","volume":"351","author":"MB Leonard","year":"2004","unstructured":"Leonard MB, Feldman HI, Shults J, Zemel BS, Foster BJ, Stallings VA (2004) Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 351(9):868\u2013875","journal-title":"N Engl J Med"},{"issue":"3 Pt 1","key":"9630_CR26","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1164\/ajrccm.157.3.9703080","volume":"157","author":"CE McEvoy","year":"1998","unstructured":"McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W, Griffith JM, Niewoehner DE (1998) Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157(3 Pt 1):704\u2013709","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"9630_CR27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/art.22294","volume":"56","author":"F Vries De","year":"2007","unstructured":"De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56(1):208\u2013214","journal-title":"Arthritis Rheum"},{"issue":"2","key":"9630_CR28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/nrrheum.2009.259","volume":"6","author":"J Compston","year":"2010","unstructured":"Compston J (2010) Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 6(2):82\u201388","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"9630_CR29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00223-008-9124-7","volume":"82","author":"P Vestergaard","year":"2008","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2008) Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int 82(4):249\u2013257","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"9630_CR30","doi-asserted-by":"crossref","first-page":"963","DOI":"10.7326\/0003-4819-119-10-199311150-00001","volume":"119","author":"RF Laan","year":"1993","unstructured":"Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van\u2019t Hof MA, Lemmens JA (1993) Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 119(10):963\u2013968","journal-title":"Ann Intern Med"},{"issue":"3","key":"9630_CR31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1359\/JBMR.041125","volume":"20","author":"FN Ton","year":"2005","unstructured":"Ton FN, Gunawardene SC, Lee H, Neer RM (2005) Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 20(3):464\u2013470","journal-title":"J Bone Miner Res"},{"issue":"2","key":"9630_CR32","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","volume":"102","author":"RS Weinstein","year":"1998","unstructured":"Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102(2):274\u2013282","journal-title":"J Clin Invest"},{"key":"9630_CR33","volume-title":"Primer on the metabolic bone diseases and disorders of mineral metabolism","author":"RS Weinstein","year":"2009","unstructured":"Weinstein RS (2009) Glucocorticoid-induced osteoporosis. In: MR ASB (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. John Wiley & Sons, Hoboken, NJ. doi: 10.1002\/9780470623992.ch58"},{"key":"9630_CR34","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00198-010-1194-5","volume":"21","author":"GY Rochefort","year":"2010","unstructured":"Rochefort GY, Pallu S, Benhamou CL (2010) Osteocyte: the unrecognized side of bone tissue. Osteoporosis Int 21:1457\u20131469","journal-title":"Osteoporosis Int"},{"issue":"3","key":"9630_CR35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11926-011-0173-y","volume":"13","author":"D Den Uyl","year":"2011","unstructured":"Den Uyl D, Bultink IE, Lems WF (2011) Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 13(3):233\u2013240","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"9630_CR36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bbrc.2008.12.035","volume":"379","author":"K Hayashi","year":"2009","unstructured":"Hayashi K, Yamaguchi T, Yano S, Kanazawa I, Yamauchi M, Yamamoto M, Sugimoto T (2009) BMP\/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 379(2):261\u2013266","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"9630_CR37","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/art.23454","volume":"58","author":"W Yao","year":"2008","unstructured":"Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE (2008) Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 58(6):1674\u20131686","journal-title":"Arthritis Rheum"},{"issue":"10","key":"9630_CR38","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1210\/me.2009-0069","volume":"23","author":"LC Hofbauer","year":"2009","unstructured":"Hofbauer LC, Rauner M (2009) Live and let die: molecular effects of glucocorticoids on bone cells. Mol Endocrinol 23(10):1525\u20131531","journal-title":"Mol Endocrinol"},{"issue":"8","key":"9630_CR39","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1210\/jc.85.8.2907","volume":"85","author":"RS Weinstein","year":"2000","unstructured":"Weinstein RS, Nicholas RW, Manolagas SC (2000) Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 85(8):2907\u20132912","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9630_CR40","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1359\/jbmr.2002.17.6.979","volume":"17","author":"MS Cooper","year":"2002","unstructured":"Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, Stewart PM (2002) Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 17(6):979\u2013986","journal-title":"J Bone Miner Res"},{"issue":"9","key":"9630_CR41","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00198-008-0670-7","volume":"19","author":"J Compston","year":"2008","unstructured":"Compston J, Reid DM, Boisdron J, Brandi ML, Burlet N, Cahall D, Delmas PD, Dere W, Devogelaer JP, Fitzpatrick LA, Flamion B, Goel N, Korte S, Laslop A, Mitlak B, Ormarsdottir S, Ringe J, Rizzoli R, Tsouderos Y, Van Staa T, Reginster JY (2008) Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int 19(9):1247\u20131250","journal-title":"Osteoporos Int"},{"issue":"4","key":"9630_CR42","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(4):385\u2013397","journal-title":"Osteoporos Int"},{"issue":"10","key":"9630_CR43","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX\u2014assessment and intervention thresholds for the UK. Osteoporos Int 19(10):1395\u20131408","journal-title":"Osteoporos Int"},{"issue":"3","key":"9630_CR44","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22(3):809\u2013816","journal-title":"Osteoporos Int"},{"key":"9630_CR45","doi-asserted-by":"crossref","unstructured":"Str\u00f6m O, Borgstr\u00f6m F, Kanis JA, Compston J, Cooper C, McCloskey EV, J\u00f6nsson B (2011) Osteoporosis: burden, health care provision and opportunities in the European Union. Arch Osteoporos. doi: 10.1007\/s11657-011-0060-1","DOI":"10.1007\/s11657-011-0060-1"},{"issue":"11","key":"9630_CR46","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","volume":"62","author":"JM Grossman","year":"2010","unstructured":"Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62(11):1515\u20131526","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"9630_CR47","doi-asserted-by":"crossref","unstructured":"Lekawasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstr\u00f6m F, Cooper C, Diez Perez A, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE; for the Joint IOF-ECTS GIO Guidelines Working Group (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. doi: 10.1007\/s00198-012-1958-1","DOI":"10.1007\/s00198-012-1958-1"},{"key":"9630_CR48","unstructured":"Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Doc. ref. CPMP\/EWP\/552\/95 Rev. 2. European Medicines Agency, London"},{"key":"9630_CR49","unstructured":"Committee for Medicinal Products for Human Use (CHMP) (2010) Concept paper on the need for an addendum on the clinical investigation of medicinal products intended for treatment of glucocorticoid-induced osteoporosis. Doc. ref. EMA\/CHMP\/EWP\/15912\/2010. European Medicines Agency, London"},{"key":"9630_CR50","volume-title":"Guidelines for preclinical evaluation and clinical trials in osteoporosis","author":"World Health Organization","year":"1998","unstructured":"World Health Organization (1998) Guidelines for preclinical evaluation and clinical trials in osteoporosis. WHO, Geneva, Switzerland"},{"issue":"5","key":"9630_CR51","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2265.2011.03994.x","volume":"74","author":"J Compston","year":"2011","unstructured":"Compston J (2011) Clinical question: what is the best approach to managing glucocorticoid-induced osteoporosis? Clin Endocrinol (Oxf) 74(5):547\u2013550","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"9630_CR52","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","volume":"42","author":"S Cohen","year":"1999","unstructured":"Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42(11):2309\u20132318","journal-title":"Arthritis Rheum"},{"issue":"5","key":"9630_CR53","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"KG Saag","year":"1998","unstructured":"Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339(5):292\u2013299","journal-title":"N Engl J Med"},{"issue":"4","key":"9630_CR54","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"S Wallach","year":"2000","unstructured":"Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67(4):277\u2013285","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"9630_CR55","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00198-009-0917-y","volume":"20","author":"BL Langdahl","year":"2009","unstructured":"Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR (2009) Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 20(12):2095\u20132104","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"9630_CR56","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1530\/EJE-08-0282","volume":"159","author":"NJ Shaw","year":"2008","unstructured":"Shaw NJ (2008) Management of osteoporosis in children. Eur J Endocrinol 159(Suppl 1):S33\u2013S39","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"9630_CR57","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1359\/jbmr.2003.18.5.913","volume":"18","author":"TP Van Staa","year":"2003","unstructured":"Van Staa TP, Cooper C, Leufkens HG, Bishop N (2003) Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 18(5):913\u2013918","journal-title":"J Bone Miner Res"},{"issue":"5","key":"9630_CR58","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMp038103","volume":"349","author":"JC Marini","year":"2003","unstructured":"Marini JC (2003) Do bisphosphonates make children\u2019s bones better or brittle? N Engl J Med 349(5):423\u2013426","journal-title":"N Engl J Med"},{"issue":"8","key":"9630_CR59","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3949\/ccjm.77a.10003","volume":"77","author":"RK Dore","year":"2010","unstructured":"Dore RK (2010) How to prevent glucocorticoid-induced osteoporosis. Cleve Clin J Med 77(8):529\u2013536","journal-title":"Cleve Clin J Med"},{"issue":"5","key":"9630_CR60","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s00223-001-0043-0","volume":"70","author":"ML Bianchi","year":"2002","unstructured":"Bianchi ML (2002) Glucorticoids and bone: some general remarks and some special observations in pediatric patients. Calcif Tissue Int 70(5):384\u2013390","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"9630_CR61","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s10067-008-0864-6","volume":"27","author":"Y Inoue","year":"2008","unstructured":"Inoue Y, Shimojo N, Suzuki S, Arima T, Tomiita M, Minagawa M, Kohno Y (2008) Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases. Clin Rheumatol 27(7):909\u2013912","journal-title":"Clin Rheumatol"},{"issue":"10","key":"9630_CR62","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.clinthera.2011.09.001","volume":"33","author":"M Nakhla","year":"2011","unstructured":"Nakhla M, Denker AE, Connor JD, Carpenter TO, Walson PD, Porras AG, Matthews CZ, Larson P, Freeman A, Wagner JA, Ward LM (2011) Bioavailability and short-term tolerability of alendronate in glucocorticoid-treated children. Clin Ther 33(10):1516\u20131523","journal-title":"Clin Ther"},{"key":"9630_CR63","doi-asserted-by":"crossref","unstructured":"Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury I, Rauch F, Tugwell P, Moher D (2007) Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev 4: CD005324","DOI":"10.1002\/14651858.CD005324.pub2"},{"issue":"4","key":"9630_CR64","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.rdc.2006.09.001","volume":"32","author":"JP Devogelaer","year":"2006","unstructured":"Devogelaer JP (2006) Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach. Rheum Dis Clin North Am 32(4):733\u2013757","journal-title":"Rheum Dis Clin North Am"},{"key":"9630_CR65","unstructured":"Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P (2000) Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2:CD000952"},{"issue":"8","key":"9630_CR66","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/1529-0131(199908)42:8<1740::AID-ANR25>3.0.CO;2-E","volume":"42","author":"S Amin","year":"1999","unstructured":"Amin S, LaValley MP, Simms RW, Felson DT (1999) The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 42(8):1740\u20131751","journal-title":"Arthritis Rheum"},{"issue":"6","key":"9630_CR67","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJM199708073370603","volume":"337","author":"JD Adachi","year":"1997","unstructured":"Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337(6):382\u2013387","journal-title":"N Engl J Med"},{"issue":"24","key":"9630_CR68","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1056\/NEJM199306173282404","volume":"328","author":"P Sambrook","year":"1993","unstructured":"Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J (1993) Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328(24):1747\u20131752","journal-title":"N Engl J Med"},{"issue":"6","key":"9630_CR69","first-page":"3485","volume":"28","author":"M Talalaj","year":"1996","unstructured":"Talalaj M, Gradowska L, Marcinowska-Suchowierska E, Durlik M, Gaciong Z, Lao M (1996) Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients. Transplant Proc 28(6):3485\u20133487","journal-title":"Transplant Proc"},{"issue":"10","key":"9630_CR70","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s00198-006-0158-2","volume":"17","author":"CF McDonald","year":"2006","unstructured":"McDonald CF, Zebaze RM, Seeman E (2006) Calcitriol does not prevent bone loss in patients with asthma receiving corticosteroid therapy: a double-blind placebo-controlled trial. Osteoporos Int 17(10):1546\u20131551","journal-title":"Osteoporos Int"},{"issue":"7","key":"9630_CR71","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMoa053569","volume":"355","author":"RN De Nijs","year":"2006","unstructured":"De Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen AC, Geusens PP, Bruyn GA, Dijkmans BA, Bijlsma JW (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355(7):675\u2013684","journal-title":"N Engl J Med"},{"issue":"8","key":"9630_CR72","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00198-004-1614-5","volume":"15","author":"RN De Nijs","year":"2004","unstructured":"De Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW (2004) Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15(8):589\u2013602","journal-title":"Osteoporos Int"},{"issue":"1","key":"9630_CR73","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"JD Adachi","year":"2001","unstructured":"Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44(1):202\u2013211","journal-title":"Arthritis Rheum"},{"issue":"6","key":"9630_CR74","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","volume":"15","author":"DM Reid","year":"2000","unstructured":"Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15(6):1006\u20131013","journal-title":"J Bone Miner Res"},{"issue":"3","key":"9630_CR75","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/03009749950154211","volume":"28","author":"EA Jenkins","year":"1999","unstructured":"Jenkins EA, Walker-Bone KE, Wood A, McCrae FC, Cooper C, Cawley MI (1999) The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. Scand J Rheumatol 28(3):152\u2013156","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"9630_CR76","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1210\/jc.83.4.1128","volume":"83","author":"C Roux","year":"1998","unstructured":"Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, Di Munno O, Pouilles JM, Horlait S, Cortet B (1998) Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab 83(4):1128\u20131133","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"9630_CR77","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/ard.57.12.724","volume":"57","author":"P Geusens","year":"1998","unstructured":"Geusens P, Dequeker J, Vanhoof J, Stalmans R, Boonen S, Joly J, Nijs J, Raus J (1998) Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Ann Rheum Dis 57(12):724\u2013727","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"9630_CR78","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/thx.53.5.351","volume":"53","author":"P Pitt","year":"1998","unstructured":"Pitt P, Li F, Todd P, Webber D, Pack S, Moniz C (1998) A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. Thorax 53(5):351\u2013356","journal-title":"Thorax"},{"key":"9630_CR79","doi-asserted-by":"crossref","unstructured":"Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD001155","DOI":"10.1002\/14651858.CD001155.pub2"},{"issue":"8","key":"9630_CR80","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJMoa035617","volume":"350","author":"E Shane","year":"2004","unstructured":"Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D (2004) Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350(8):767\u2013776","journal-title":"N Engl J Med"},{"issue":"3","key":"9630_CR81","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10165-008-0055-y","volume":"18","author":"S Takeda","year":"2008","unstructured":"Takeda S, Kaneoka H, Saito T (2008) Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol. Mod Rheumatol 18(3):271\u2013276","journal-title":"Mod Rheumatol"},{"issue":"5","key":"9630_CR82","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1359\/jbmr.2003.18.5.919","volume":"18","author":"PN Sambrook","year":"2003","unstructured":"Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, Eisman JA, Nicholson GC (2003) Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 18(5):919\u2013924","journal-title":"J Bone Miner Res"},{"issue":"11","key":"9630_CR83","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3899\/jrheum.080168","volume":"35","author":"Y Okada","year":"2008","unstructured":"Okada Y, Nawata M, Nakayamada S, Saito K, Tanaka Y (2008) Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. J Rheumatol 35(11):2249\u20132254","journal-title":"J Rheumatol"},{"issue":"4","key":"9630_CR84","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00223-001-1060-8","volume":"69","author":"DM Reid","year":"2001","unstructured":"Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69(4):242\u2013247","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"9630_CR85","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002239900334","volume":"61","author":"Y Boutsen","year":"1997","unstructured":"Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogelaer JP (1997) Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int 61(4):266\u2013271","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"9630_CR86","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1359\/jbmr.2001.16.1.104","volume":"16","author":"Y Boutsen","year":"2001","unstructured":"Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP (2001) Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3\u00a0months, and calcium alone. J Bone Miner Res 16(1):104\u2013112","journal-title":"J Bone Miner Res"},{"issue":"9671","key":"9630_CR87","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373(9671):1253\u20131263","journal-title":"Lancet"},{"issue":"10","key":"9630_CR88","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","volume":"14","author":"JD Ringe","year":"2003","unstructured":"Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F (2003) Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 14(10):801\u2013807","journal-title":"Osteoporos Int"},{"issue":"2","key":"9630_CR89","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1258\/mi.2011.011014","volume":"17","author":"RJ Hollick","year":"2011","unstructured":"Hollick RJ, Reid DM (2011) Role of bisphosphonates in the management of postmenopausal osteoporosis: an update on recent safety anxieties. Menopause Int 17(2):66\u201372","journal-title":"Menopause Int"},{"issue":"1","key":"9630_CR90","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3899\/jrheum.090411","volume":"37","author":"JP Devogelaer","year":"2010","unstructured":"Devogelaer JP, Adler RA, Recknor C, See K, Warner MR, Wong M, Krohn K (2010) Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol 37(1):141\u2013148","journal-title":"J Rheumatol"},{"issue":"20","key":"9630_CR91","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357(20):2028\u20132039","journal-title":"N Engl J Med"},{"issue":"11","key":"9630_CR92","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60(11):3346\u20133355","journal-title":"Arthritis Rheum"},{"issue":"19","key":"9630_CR93","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434\u20131441","journal-title":"N Engl J Med"},{"issue":"8","key":"9630_CR94","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","volume":"102","author":"NE Lane","year":"1998","unstructured":"Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102(8):1627\u20131633","journal-title":"J Clin Invest"},{"key":"9630_CR95","doi-asserted-by":"crossref","unstructured":"Rizzoli R, Reginster JY, Boonen S, Breart G, Diez-Perez A, Felsenberg D, Kaufman JM, Kanis JA, Cooper C (2011) Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcified Tissue Int 89:91\u2013104","DOI":"10.1007\/s00223-011-9499-8"},{"issue":"23","key":"9630_CR96","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","volume":"337","author":"PD Delmas","year":"1997","unstructured":"Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337(23):1641\u20131647","journal-title":"N Engl J Med"},{"issue":"7","key":"9630_CR97","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 282(7):637\u2013645","journal-title":"JAMA"},{"issue":"5","key":"9630_CR98","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/ard.2010.143453","volume":"70","author":"CC Mok","year":"2011","unstructured":"Mok CC, Ying KY, To CH, Ho LY, Yu KL, Lee HK, Ma KM (2011) Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis 70(5):778\u2013784","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"9630_CR99","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459\u2013468","journal-title":"N Engl J Med"},{"issue":"5","key":"9630_CR100","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","volume":"90","author":"JY Reginster","year":"2005","unstructured":"Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816\u20132822","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9630_CR101","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00223-010-9363-2","volume":"86","author":"P Sun","year":"2010","unstructured":"Sun P, Cai DH, Li QN, Chen H, Deng WM, He L, Yang L (2010) Effects of alendronate and strontium ranelate on cancellous and cortical bone mass in glucocorticoid-treated adult rats. Calcif Tissue Int 86(6):495\u2013501","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"9630_CR102","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2):165\u2013176","journal-title":"Cell"},{"issue":"2","key":"9630_CR103","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2):309\u2013319","journal-title":"Cell"},{"issue":"8","key":"9630_CR104","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765","journal-title":"N Engl J Med"},{"issue":"10","key":"9630_CR105","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/en.140.10.4382","volume":"140","author":"LC Hofbauer","year":"1999","unstructured":"Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140(10):4382\u20134389","journal-title":"Endocrinology"},{"issue":"3","key":"9630_CR106","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1359\/JBMR.041233","volume":"20","author":"S Sivagurunathan","year":"2005","unstructured":"Sivagurunathan S, Muir MM, Brennan TC, Seale JP, Mason RS (2005) Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res 20(3):390\u2013398","journal-title":"J Bone Miner Res"},{"issue":"1","key":"9630_CR107","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1677\/joe.0.1590191","volume":"159","author":"NO Vidal","year":"1998","unstructured":"Vidal NO, Brandstrom H, Jonsson KB, Ohlsson C (1998) Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J Endocrinol 159(1):191\u2013195","journal-title":"J Endocrinol"},{"issue":"9","key":"9630_CR108","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1210\/en.2011-0170","volume":"152","author":"RS Weinstein","year":"2011","unstructured":"Weinstein RS, O\u2019Brien CA, Almeida M, Zhao H, Roberson PK, Jilka RL, Manolagas SC (2011) Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice. Endocrinology 152(9):3323\u20133331","journal-title":"Endocrinology"},{"issue":"5","key":"9630_CR109","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/art.24445","volume":"60","author":"LC Hofbauer","year":"2009","unstructured":"Hofbauer LC, Zeitz U, Schoppet M, Skalicky M, Schuler C, Stolina M, Kostenuik PJ, Erben RG (2009) Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum 60(5):1427\u20131437","journal-title":"Arthritis Rheum"},{"issue":"10","key":"9630_CR110","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/nm.2452","volume":"17","author":"T Nakashima","year":"2011","unstructured":"Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17(10):1231\u20131234","journal-title":"Nat Med"},{"issue":"10","key":"9630_CR111","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nm.2448","volume":"17","author":"J Xiong","year":"2011","unstructured":"Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O\u2019Brien CA (2011) Matrix-embedded cells control osteoclast formation. Nat Med 17(10):1235\u20131241","journal-title":"Nat Med"},{"issue":"5","key":"9630_CR112","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","volume":"58","author":"SB Cohen","year":"2008","unstructured":"Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58(5):1299\u20131309","journal-title":"Arthritis Rheum"},{"issue":"5","key":"9630_CR113","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/ard.2009.112920","volume":"69","author":"RK Dore","year":"2010","unstructured":"Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, Wang H, Tsuji W, Newmark R (2010) Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 69(5):872\u2013875","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"9630_CR114","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1096\/fj.11-182519","volume":"25","author":"J Jia","year":"2011","unstructured":"Jia J, Yao W, Guan M, Dai W, Shahnazari M, Kar R, Bonewald L, Jiang JX, Lane NE (2011) Glucocorticoid dose determines osteocyte cell fate. FASEB J 25(10):3366\u20133376","journal-title":"FASEB J"},{"issue":"1","key":"9630_CR115","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/sj.clpt.6100450","volume":"83","author":"SA Stoch","year":"2008","unstructured":"Stoch SA, Wagner JA (2008) Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther 83(1):172\u2013176","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"9630_CR116","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1002\/art.30385","volume":"63","author":"M Marenzana","year":"2011","unstructured":"Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, Robinson MK (2011) Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum 63(8):2385\u20132395","journal-title":"Arthritis Rheum"},{"issue":"12","key":"9630_CR117","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/jbmr.151","volume":"25","author":"AH Van Lierop","year":"2010","unstructured":"Van Lierop AH, Hamdy NA, Papapoulos SE (2010) Glucocorticoids are not always deleterious for bone. J Bone Miner Res 25(12):2796\u20132800","journal-title":"J Bone Miner Res"},{"issue":"12","key":"9630_CR118","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1073\/pnas.0812308106","volume":"106","author":"AN Gerber","year":"2009","unstructured":"Gerber AN, Masuno K, Diamond MI (2009) Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening. Proc Natl Acad Sci USA 106(12):4929\u20134934","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"9630_CR119","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1096\/fj.10-173393","volume":"25","author":"A Rauch","year":"2011","unstructured":"Rauch A, Gossye V, Bracke D, Gevaert E, Jacques P, Van Beneden K, Vandooren B, Rauner M, Hofbauer LC, Haegeman G, Elewaut D, Tuckermann JP, De Bosscher K (2011) An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. FASEB J 25(4):1323\u20131332","journal-title":"FASEB J"},{"issue":"8","key":"9630_CR120","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/jbmr.5650080810","volume":"8","author":"N Morrison","year":"1993","unstructured":"Morrison N, Eisman J (1993) Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter. J Bone Miner Res 8(8):969\u2013975","journal-title":"J Bone Miner Res"},{"issue":"2","key":"9630_CR121","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1042\/CS20040070","volume":"107","author":"MS Cooper","year":"2004","unstructured":"Cooper MS (2004) Sensitivity of bone to glucocorticoids. Clin Sci (Lond) 107(2):111\u2013123","journal-title":"Clin Sci (Lond)"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-012-9630-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-012-9630-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-012-9630-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T07:41:04Z","timestamp":1558683664000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-012-9630-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,10]]},"references-count":121,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["9630"],"URL":"https:\/\/doi.org\/10.1007\/s00223-012-9630-5","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,10]]}}}